SecBot SecBot
8-K ·Filed Nov 4, 2026

PGEN

PRECIGEN, INC.
BULLISH
Impact 6/10
Horizonweeks Processed12d 7h ago SEC0000950103-26-016970
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

PAPZIMEOS revenue growth trajectory and positive cash flow achievement are the key metrics to track. Monitor the pace of patient hub enrollment and conversion to treated patients, as well as the EMA MAA decision for European expansion.

DirectionBullish
Confidencehigh
Horizonweeks

PAPZIMEOS

● Neutral Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercially launched (August 2025).
Next catalyst
None dated

What to watchWatch for the pace of PAPZIMEOS revenue growth in upcoming quarterly reports, particularly whether the drug can maintain its 37% sequential growth trajectory against the new competition from Inovio's VOCERYQ, which was approved on October 30, 2026. Also monitor for a potential EMA marketing authorization application decision for European expansion, which could open a new market.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$4.22
T+0 close · Nov 4, 2026 · via day close
Latest settled
+10.43%
T+5 · $4.66 · next T+20 in 17d
Vs SPY
+7.14%
α at T+5
Latest observation
−1.26%
T+7 · FF3 residual α
  1. T+0 · Nov 5 $4.22entry
  2. T+1 · 11d ago +5.92%α +5.61% · $4.47
  3. T+5 · 5d ago +10.43%α +7.14% · $4.66
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Precigen reported Q3 2026 revenue of $74.1M (vs. $71.6M consensus) and GAAP diluted EPS of $0.08 (in line with consensus). PAPZIMEOS net revenue grew 37% sequentially to $72.9M, and the company achieved positive operating cash flow of $11.9M, a full quarter ahead of guidance. Net income was $35.8M, a major swing from a $146.3M net loss in Q3 2025.

Key Financial Metrics

EPS
$0.08
est $0.08 · 0.0%
Revenue
$74.1M
est $71.6M · +3.6% · +2437.0% YoY
Rating
in line

Key Facts

  • PAPZIMEOS net revenue of $72.9M in Q3 2026, up 37% sequentially from $21.6M in Q1 2026
  • Total revenue of $74.1M vs. $71.6M consensus
  • GAAP diluted EPS of $0.08, in line with $0.08 consensus
  • Net income of $35.8M vs. net loss of $146.3M in Q3 2025
  • Positive operating cash flow of $11.9M, achieved a full quarter ahead of guidance
  • Cash, cash equivalents and investments of $51.0M as of September 30, 2026
  • FDA Platform Technology Designation granted to AdenoVerse platform in September 2026
  • Launch-to-date PAPZIMEOS net product revenue of $151M

Financial Impact

PAPZIMEOS revenue of $72.9M, total revenue $74.1M, net income $35.8M, operating cash flow $11.9M

revenueepscash flow

Risk Factors

  • Dependence on single product PAPZIMEOS for revenue
  • PAPZIMEOS revenue concentration with trade receivables of $96.5M (collection risk)
  • Long-term debt of $94.3M remains on balance sheet
  • Pipeline stage candidates (PRGN-2009) are still in Phase 2 with no near-term revenue

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000950103-26-016970
Document: dp256359_8k.htm0000950103-26-016970
Document: 0000950103-26-016970-index-headers.html0000950103-26-016970
Document: 0000950103-26-016970-index.html0000950103-26-016970
Document: 0000950103-26-016970.txt0000950103-26-016970
8-K Data (Synthetic)0000950103-26-016970

Track record

13 reports on PGEN

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +52.17% at T+60 after the May 13, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 4, 202612d ago 8-K Bullish 6/10 Viewing Entry $4.22 to $4.66 Now $4.30 +1.90% ▲ +10.43% +7.14% vs SPY
  2. Aug 28, 202611w ago Insider Cluster Neutral 3/10 Entry $6.93 to $6.99 Now $4.30 −37.95% ▲ +0.79% +0.94% vs SPY
  3. Aug 26, 202611w ago 144 Neutral 3/10 Entry $7.19 to $7.14 Now $4.30 −40.19% ▼ −0.70% −0.96% vs SPY
  4. Aug 25, 202611w ago Insider Cluster Bearish 4/10 Entry $7.42 to $7.01 Now $4.30 +42.05% ▲ +5.53% +5.41% vs SPY
  5. Aug 25, 202611w ago Insider Cluster Neutral 2/10 Entry $7.42 to $7.01 Now $4.30 −42.05% ▼ −5.53% −5.41% vs SPY
  6. Aug 7, 202614w ago Insider Cluster Neutral 2/10 Entry $7.00 to $6.55 Now $4.30 −38.57% ▼ −6.43% −6.38% vs SPY
  7. Aug 3, 202615w ago Insider Cluster Neutral 2/10 Entry $6.53 to $6.86 Now $4.30 −34.15% ▲ +5.05% +5.15% vs SPY
  8. Jul 1, 202619w ago Insider Cluster Bearish 5/10 Entry $5.64 to $5.53 Now $4.30 +23.76% ▲ +1.95% +2.88% vs SPY
  9. Jun 24, 202620w ago 8-K Neutral 3/10 Entry $5.52 to $5.25 Now $4.30 −22.10% ▼ −4.89% −6.45% vs SPY
  10. Jun 1, 202624w ago Insider Cluster Neutral 3/10 Entry $3.86 to $3.71 Now $4.30 +11.40% ▼ −3.89% −0.92% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026